Your browser doesn't support javascript.
loading
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta, Marco; Cesta, Novella; Stingone, Christof; Malagnino, Vincenzo; Teti, Elisabetta; Vitale, Pietro; De Simone, Giuseppe; Rossi, Benedetta; Ansaldo, Lorenzo; Compagno, Mirko; Spalliera, Ilaria; Di Lorenzo, Andrea; Landi, Doriana; Nicoletti, Carolina Gabri; Marfia, Girolama Alessandra; Andreoni, Massimo; Sarmati, Loredana.
Afiliação
  • Iannetta M; Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy. Electronic address: marco.iannetta@uniroma2.it.
  • Cesta N; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Stingone C; Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy.
  • Malagnino V; Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy.
  • Teti E; Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy.
  • Vitale P; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • De Simone G; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Rossi B; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Ansaldo L; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Compagno M; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Spalliera I; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Di Lorenzo A; Department of System Medicine, Tor Vergata University, Rome, Italy.
  • Landi D; Department of System Medicine, Tor Vergata University, Rome, Italy; Multiple Sclerosis and Research Unit, Policlinico Tor Vergata, Rome, Italy.
  • Nicoletti CG; Department of System Medicine, Tor Vergata University, Rome, Italy; Multiple Sclerosis and Research Unit, Policlinico Tor Vergata, Rome, Italy.
  • Marfia GA; Department of System Medicine, Tor Vergata University, Rome, Italy; Multiple Sclerosis and Research Unit, Policlinico Tor Vergata, Rome, Italy.
  • Andreoni M; Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy.
  • Sarmati L; Department of System Medicine, Tor Vergata University, Rome, Italy; Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy.
Mult Scler Relat Disord ; 45: 102442, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32777745
ABSTRACT

BACKGROUND:

Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).

OBJECTIVES:

to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.

METHODS:

Case series.

RESULTS:

Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.

CONCLUSION:

Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Hospedeiro Imunocomprometido / Infecções por Coronavirus / Anticorpos Monoclonais Humanizados / Fatores Imunológicos / Esclerose Múltipla Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Hospedeiro Imunocomprometido / Infecções por Coronavirus / Anticorpos Monoclonais Humanizados / Fatores Imunológicos / Esclerose Múltipla Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article